Format

Send to

Choose Destination
Am J Psychiatry. 2005 Feb;162(2):386-8.

Improved p50 auditory gating with ondansetron in medicated schizophrenia patients.

Author information

1
Denver VA Medical Center, 1055 Clermont St., Denver, CO 80220, USA. Lawrence.Adler@med.va.gov

Abstract

OBJECTIVE:

Most schizophrenia patients have a deficit in auditory sensory gating, which appears to be mediated by the alpha-7 nicotinic receptor, that is not improved with conventional antipsychotic treatment. This study examined the effects of ondansetron, a highly selective 5-HT3 antagonist, on the P50 auditory evoked potential.

METHOD:

Eight medicated outpatients with schizophrenia were given either ondansetron (16 mg) or placebo in a double-blind, placebo-controlled design. Evoked potentials were recorded at baseline and 1 hour, 2 hours, and 3 hours after receipt of drug.

RESULTS:

There was a highly significant improvement in P50 gating after ondansetron treatment. The maximal treatment difference was at 2 hours posttreatment (ondansetron: mean=41.4%, SD=39.7%; placebo: mean=80.2%, SD=21.3%).

CONCLUSIONS:

Ondansetron significantly enhanced P50 auditory gating in schizophrenia patients treated with typical antipsychotics.

PMID:
15677607
DOI:
10.1176/appi.ajp.162.2.386
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center